See more : Neogen Chemicals Limited (NEOGEN.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Alpha Cognition Inc. (ACOGF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alpha Cognition Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bentley Capital Limited (BEL.AX) Income Statement Analysis – Financial Results
- Artis Real Estate Investment Trust (ARESF) Income Statement Analysis – Financial Results
- Skylark Holdings Co., Ltd. (3197.T) Income Statement Analysis – Financial Results
- JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. (JSP.BK) Income Statement Analysis – Financial Results
- Hua Eng Wire & Cable Co., Ltd. (1608.TW) Income Statement Analysis – Financial Results
Alpha Cognition Inc. (ACOGF)
About Alpha Cognition Inc.
Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 86.03K | 87.32K | 89.09K | 85.75K | 0.00 | 0.00 |
| Gross Profit | -86.03K | -87.32K | -89.09K | -85.75K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.92M | 8.82M | 7.97M | 4.67M | 3.56M | 0.00 |
| General & Administrative | 4.50M | 4.53M | 3.40M | 950.71K | 391.47K | 0.00 |
| Selling & Marketing | 19.79K | 31.73K | 103.25K | 0.00 | 98.31K | 0.00 |
| SG&A | 4.71M | 4.56M | 3.51M | 950.71K | 1.52M | 32.46K |
| Other Expenses | 0.00 | 0.00 | -1.40M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.71M | 13.47M | 11.57M | 5.71M | 5.47M | 32.46K |
| Cost & Expenses | 9.71M | 13.47M | 11.57M | 5.71M | 5.47M | 32.46K |
| Interest Income | 6.93K | 1.93K | 2.07K | 22.59K | 8.13K | 0.00 |
| Interest Expense | 68.95K | 172.88K | 528.16K | 770.37K | 0.00 | 0.00 |
| Depreciation & Amortization | 84.48K | 87.32K | 89.09K | 85.75K | 79.04K | 0.00 |
| EBITDA | -9.71M | -13.13M | -11.03M | -5.69M | -5.08M | -32.46K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.71M | -13.46M | -11.57M | -5.68M | -5.16M | -32.46K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.07M | 1.01M | -8.51M | -96.58K | -1.52M | 0.00 |
| Income Before Tax | -13.77M | -12.11M | -19.55M | -5.78M | -6.61M | -32.46K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 172.88K | 528.16K | 770.37K | -78.45 | 0.00 |
| Net Income | -13.77M | -12.11M | -19.55M | -5.78M | -6.61M | -32.46K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.15 | -0.18 | -0.37 | -0.96 | -0.21 | -0.03 |
| EPS Diluted | -0.15 | -0.18 | -0.37 | -0.96 | -0.21 | -0.03 |
| Weighted Avg Shares Out | 94.36M | 67.97M | 53.33M | 6.02M | 31.46M | 1.19M |
| Weighted Avg Shares Out (Dil) | 94.36M | 67.97M | 53.33M | 6.02M | 31.46M | 1.19M |
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (CSE: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter and six months ended September 30, 2024,...
Alpha Cognition Announces Appointment of VP Finance and Accounting
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, announces that Henry Du has joined Alpha Cognition as the VP of Finance...
Alpha Cognition Announces Change of Officer
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, announces that Don Kalkofen has resigned as the Chief Financial Officer of the...
Spartan Capital Securities Serves as Selling Group Member in Alpha Cognition Inc.'s $4.454 Million Convertible Note and Warrants Bridge Financing
New York, NY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities LLC, a leading investment banking firm, is pleased to announce its role as a selling group member in Alpha Cognition Inc.'s successful $4.454 million bridge financing. The offering,...
Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the closing of a $4.545 million bridge financing through the offer...
Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, announced today its decision to temporarily delay its planned capital raise and uplisting...
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (OTCQB: ACOG) (CSE: ACOG) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter and six months ended June 30, 2024,...
Alpha Cognition Announces First Quarter of 2024 Results and Provides Corporate Update
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results...
Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results...
Alpha Cognition to Present at the Emerging Growth Conference on April 3, 2024 at 12:00pm EDT.
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that it will present at the Emerging Growth Conference on April 3, 2024. The company invites...
Source: https://incomestatements.info
Category: Stock Reports